Volume 9, Issue 4 (2025)
SJMR 2025, 9(4): 201-210 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nateghi M R, Sanaye Naderi M, saremi A. Preeclampsia Management by Magnesium Sulfate: The Sarem Women’s Hospital Protocol. SJMR 2025; 9 (4) : 2
URL: http://saremjrm.com/article-1-347-en.html
URL: http://saremjrm.com/article-1-347-en.html
1- Sarem Gynecology, Obstetrics and Infertility Research Center, Sarem Women’s Hospital, Iran University of Medical Science (IUMS), Tehran, Iran. & Sarem Cell Research Center (SCRC), Sarem Women’s Hospital, Tehran, Iran.
2- Sarem Gynecology, Obstetrics and Infertility Research Center, Sarem Women’s Hospital, Iran University of Medical Science (IUMS), Tehran, Iran. & Sarem Gynecology, Obstetrics and Infertility Research Center, Sarem Women’s Hospital, Iran University of Medical Science (IUMS), Tehran, Iran.
2- Sarem Gynecology, Obstetrics and Infertility Research Center, Sarem Women’s Hospital, Iran University of Medical Science (IUMS), Tehran, Iran. & Sarem Gynecology, Obstetrics and Infertility Research Center, Sarem Women’s Hospital, Iran University of Medical Science (IUMS), Tehran, Iran.
Abstract: (1346 Views)
Introduction: Preeclampsia and eclampsia are among the top three causes of maternal mortality worldwide, accounting for 10 to 25% of such deaths. Preeclampsia is defined as a condition in pregnant women at or beyond 20 weeks of gestation, characterized by a diastolic blood pressure of 90 mmHg or higher and significant proteinuria. In 1925, magnesium sulfate was introduced into clinical practice to treat eclampsia. The primary objective of this study was to present the successful protocol for magnesium sulfate dosage in the treatment of preeclampsia in the study population, resulting in zero mortality at the Sarem Women’s Hospital in Tehran.
Materials and Methods: According to this protocol, mothers with non-severe preeclampsia were hospitalized, and decisions were made based on gestational age, with initial care provided. After initial care, if the gestational age was 37 weeks or more, labor induction was initiated, and magnesium sulfate was administered during the active phase of labor. However, if the gestational age was less than 37 weeks, symptoms were closely monitored, and initial care was continued until delivery. The primary medication for controlling and preventing seizures was magnesium sulfate, administered at a dose of 4 to 6 grams dissolved in 100 ml of Ringer's solution or normal saline throughout 15 to 20 minutes. Due to the high dose of magnesium sulfate, monitoring for toxicity was conducted, and calcium gluconate was readily available.
Results: A 10-year review of data from Sarem Women’s Hospital showed that among 41,102 patient visits, 463 cases were severe preeclampsia and 166 cases were mild preeclampsia. With the implementation of this treatment protocol, the mortality rate reached zero. This statistic is considered a significant achievement for the institution. The majority of the patients were primigravida (gravida 1) and nulliparous (para 0), with no reported abortions. 90% of the pregnancies involved singletons, and proteinuria was not commonly observed. Fetal hypoxia was reported in only one case, and most cases did not have intrauterine growth restriction (IUGR). None of the newborns had congenital anomalies.
Conclusion: The Sarem Women’s Hospital's magnesium sulfate protocol for the management of preeclampsia is a completely safe treatment method that has reduced mortality to zero and is associated with minimal maternal and fetal complications. It can be a suitable treatment protocol for use in all medical centers for the control of preeclampsia.
Materials and Methods: According to this protocol, mothers with non-severe preeclampsia were hospitalized, and decisions were made based on gestational age, with initial care provided. After initial care, if the gestational age was 37 weeks or more, labor induction was initiated, and magnesium sulfate was administered during the active phase of labor. However, if the gestational age was less than 37 weeks, symptoms were closely monitored, and initial care was continued until delivery. The primary medication for controlling and preventing seizures was magnesium sulfate, administered at a dose of 4 to 6 grams dissolved in 100 ml of Ringer's solution or normal saline throughout 15 to 20 minutes. Due to the high dose of magnesium sulfate, monitoring for toxicity was conducted, and calcium gluconate was readily available.
Results: A 10-year review of data from Sarem Women’s Hospital showed that among 41,102 patient visits, 463 cases were severe preeclampsia and 166 cases were mild preeclampsia. With the implementation of this treatment protocol, the mortality rate reached zero. This statistic is considered a significant achievement for the institution. The majority of the patients were primigravida (gravida 1) and nulliparous (para 0), with no reported abortions. 90% of the pregnancies involved singletons, and proteinuria was not commonly observed. Fetal hypoxia was reported in only one case, and most cases did not have intrauterine growth restriction (IUGR). None of the newborns had congenital anomalies.
Conclusion: The Sarem Women’s Hospital's magnesium sulfate protocol for the management of preeclampsia is a completely safe treatment method that has reduced mortality to zero and is associated with minimal maternal and fetal complications. It can be a suitable treatment protocol for use in all medical centers for the control of preeclampsia.
Article number: 2
Keywords: ش
Article Type: Original Research |
Subject:
Childbirth
Received: 2024/12/30 | Accepted: 2025/02/13 | Published: 2025/03/6
Received: 2024/12/30 | Accepted: 2025/02/13 | Published: 2025/03/6
Blood pressure during pregnancy [JPG 2836 KB] (66 Download)
Magnesium sulfate protocol [JPG 557 KB] (98 Download)
References
1. Abalos E, et al., Global and regional estimates of preeclampsia and eclampsia: a systematic review. European journal of obstetrics & gynecology and reproductive biology, 2013. 170(1): p. 1-7. [DOI:10.1016/j.ejogrb.2013.05.005] [PMID]
2. Duley L. The global impact of pre-eclampsia and eclampsia. in Seminars in perinatology. 2009. Elsevier. [DOI:10.1053/j.semperi.2009.02.010] [PMID]
3. Jana N, Barik S, and Arora N, Re: Clinical practice patterns on the use of magnesium sulphate for treatment of pre-eclampsia and eclampsia: a multi-country survey: Magnesium sulphate regimens for eclampsia: should we adopt same'gold standard'for all women? BJOG: an international journal of obstetrics and gynaecology, 2018. 125(7): p. 909. [DOI:10.1111/1471-0528.15149] [PMID]
4. Vest AR and Cho LS, Hypertension in pregnancy. Current atherosclerosis reports, 2014. 16(3): p. 1-11. [DOI:10.1007/s11883-013-0395-8] [PMID]
5. Pauli JM and Repke JT, Pitfalls With the New American College of Obstetricians and Gynecologists Task Force on Hypertension in Pregnancy. Clinical obstetrics and gynecology, 2017. 60(1): p. 141-152. [DOI:10.1097/GRF.0000000000000247] [PMID]
6. Lindheimer MD and Umans JG, Explaining and predicting preeclampsia. New England journal of medicine, 2006. 355(10): p. 1056-1057. [DOI:10.1056/NEJMe068161] [PMID]
7. Tessema GA, Tekeste A, and Ayele TA, Preeclampsia and associated factors among pregnant women attending antenatal care in Dessie referral hospital, Northeast Ethiopia: a hospital-based study. BMC pregnancy and childbirth, 2015. 15(1): p. 1-7. [DOI:10.1186/s12884-015-0502-7] [PMID] []
8. Nour NM, An introduction to maternal mortality. Reviews in obstetrics and gynecology, 2008. 1(2): p. 77.
9. Osungbade KO and Ige OK, Public health perspectives of preeclampsia in developing countries: implication for health system strengthening. Journal of pregnancy, 2011. 2011. [DOI:10.1155/2011/481095] [PMID] []
10. Belay AS and Wudad T, Prevalence and associated factors of pre-eclampsia among pregnant women attending anti-natal care at Mettu Karl referal hospital, Ethiopia: cross-sectional study. Clinical hypertension, 2019. 25(1): p. 1-8. [DOI:10.1186/s40885-019-0120-1] [PMID] []
11. Phupong V, et al., Predicting the risk of preeclampsia and small for gestational age infants by uterine artery Doppler in low-risk women. Archives of gynecology and obstetrics, 2003. 268(3): p. 158-161. [DOI:10.1007/s00404-002-0361-0] [PMID]
12. Lin S, et al., Uterine artery Doppler velocimetry in relation to trophoblast migration into the myometrium of the placental bed. Obstetrics & Gynecology, 1995. 85(5): p. 760-765. [DOI:10.1016/0029-7844(95)00020-R] [PMID]
13. Akter K and Khanum H, Prevalance of pre-eclampsia and factors responsible among third trimester pregnant women in hospital of dhaka. Biomedical Journal of Scientific & Technical Research, 2021. 33(4): p. 26089-26097. [DOI:10.26717/BJSTR.2021.33.005445]
14. Wallis AB, et al., Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. American journal of hypertension, 2008. 21(5): p. 521-526. [DOI:10.1038/ajh.2008.20] [PMID]
15. Magee LA, et al., SOGC hypertension guideline committee. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can, 2014. 36(7): p. 575-576.
https://doi.org/10.1016/S1701-2163(15)30532-6 [DOI:10.1016/S1701-2163(15)30533-8]
16. Organization WH, WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia: summary of recommendations. 2011, World Health Organization.
17. Duley L, et al., Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane database of systematic reviews, 2010(11). [DOI:10.1002/14651858.CD000025.pub2]
18. Long Q, et al., Clinical practice patterns on the use of magnesium sulphate for treatment of pre‐eclampsia and eclampsia: a multi‐country survey. BJOG: An International Journal of Obstetrics & Gynaecology, 2017. 124(12): p. 1883-1890. [DOI:10.1111/1471-0528.14400] [PMID] []
19. Gómez-Sánchez PI, et al., Clinical Practice Guidelines for the prevention, early detection and treatment of complications of pregnancy delivery or the post-partum period: introduction and methodology. Revista Colombiana de Obstetricia y Ginecología, 2013. 64(3): p. 234-244. [DOI:10.18597/rcog.105]
20. Smith JM, et al., Are national policies and programs for prevention and management of postpartum hemorrhage and preeclampsia adequate? A key informant survey in 37 countries. Global Health: Science and Practice, 2014. 2(3): p. 275-284. [DOI:10.9745/GHSP-D-14-00034] [PMID] []
21. Bigdeli M, et al., Health system barriers to access and use of magnesium sulfate for women with severe pre-eclampsia and eclampsia in Pakistan: evidence for policy and practice. PloS one, 2013. 8(3): p. e59158. [DOI:10.1371/journal.pone.0059158] [PMID] []
22. Oguntunde O, et al., Factors influencing the use of magnesium sulphate in pre-eclampsia/eclampsia management in health facilities in Northern Nigeria: a mixed methods study. BMC pregnancy and childbirth, 2015. 15(1): p. 1-8. [DOI:10.1186/s12884-015-0554-8] [PMID] []
23. Tran DN and Bero LA, Barriers and facilitators to the quality use of essential medicines for maternal health in low-resource countries: An Ishikawa framework. Journal of global health, 2015. 5(1). [DOI:10.7189/jogh.05.010406] [PMID] []
24. Barua A, et al., Facility and personnel factors influencing magnesium sulfate use for eclampsia and pre‐eclampsia in 3 Indian hospitals. International Journal of Gynecology & Obstetrics, 2011. 115(3): p. 231-234. [DOI:10.1016/j.ijgo.2011.07.016] [PMID]
25. Firoz T, et al., Pre-eclampsia in low and middle income countries. Best practice & research Clinical obstetrics & gynaecology, 2011. 25(4): p. 537-548. [DOI:10.1016/j.bpobgyn.2011.04.002] [PMID]
26. Souza JP, et al., Moving beyond essential interventions for reduction of maternal mortality (the WHO Multicountry Survey on Maternal and Newborn Health): a cross-sectional study. The Lancet, 2013. 381(9879): p. 1747-1755. [DOI:10.1016/S0140-6736(13)60686-8] [PMID]
27. Group TETC, Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. The Lancet, 1995. 345(8963): p. 1455-1463. [DOI:10.1016/S0140-6736(95)91034-4]
28. Lucas MJ, Leveno KJ, and Cunningham FG, A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. New England Journal of Medicine, 1995. 333(4): p. 201-205. [DOI:10.1056/NEJM199507273330401] [PMID]
29. Chen F-P, Chang S-D, and Chu K-K, Expectant management in severe preeclampsia: does magnesium sulfate prevent the development of eclampsia? Acta obstetricia et gynecologica Scandinavica, 1995. 74(3): p. 181-185. [DOI:10.3109/00016349509008935] [PMID]
30. Sibai BM, Diagnosis and management of gestational hypertension and preeclampsia. Obstetrics & Gynecology, 2003. 102(1): p. 181-192.
https://doi.org/10.1016/S0029-7844(03)00475-7 [DOI:10.1097/00006250-200307000-00033] [PMID]
31. Isler CM, et al., Postpartum seizure prophylaxis: using maternal clinical parameters to guide therapy. Obstetrics & Gynecology, 2003. 101(1): p. 66-69.
https://doi.org/10.1016/S0029-7844(02)02317-7 [DOI:10.1097/00006250-200301000-00015] [PMID]
32. Ascarelli MH, et al., Individually determined postpartum magnesium sulfate therapy with clinical parameters to safely and cost-effectively shorten treatment for pre-eclampsia. American journal of obstetrics and gynecology, 1998. 179(4): p. 952-956. [DOI:10.1016/S0002-9378(98)70195-4] [PMID]
33. Organization WH, WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. 2011.
34. Sharafi S, et al., Comparing the efficacy of two methods sulfate magnesium therapy in improving the preeclampsia. Iranian Journal of Obstetrics, Gynecology and Infertility, 2011. 13(6): p. 6-10.
35. Kashanian M, et al., A comparison between the two methods of magnesium sulfate administration for duration of 12 versus 24 h after delivery in patients with severe preeclampsia. The Journal of Maternal-Fetal & Neonatal Medicine, 2016. 29(14): p. 2282-2287. [DOI:10.3109/14767058.2015.1083547] [PMID]
36. Fontenot MT, et al., A prospective randomized trial of magnesium sulfate in severe preeclampsia: use of diuresis as a clinical parameter to determine the duration of postpartum therapy. American Journal of Obstetrics and Gynecology, 2005. 192(6): p. 1788-1793. [DOI:10.1016/j.ajog.2004.12.056] [PMID]
37. Tukur J, The use of magnesium sulphate for the treatment of severe pre-eclampsia and eclampsia. Annals of African Medicine, 2009. 8(2). [DOI:10.4103/1596-3519.56232] [PMID]
38. Pritchard JA, Cunningham FG, and Pritchard SA, The Parkland Memorial Hospital protocol for treatment of eclampsia: evaluation of 245 cases. American journal of obstetrics and gynecology, 1984. 148(7): p. 951-963. [DOI:10.1016/0002-9378(84)90538-6] [PMID]
39. Zuspan FP, Problems encountered in the treatment of pregnancy-induced hypertension: A point of view. American journal of obstetrics and gynecology, 1978. 131(6): p. 591-597. [DOI:10.1016/0002-9378(78)90816-5] [PMID]
40. Okusanya B, et al., Clinical pharmacokinetic properties of magnesium sulphate in women with pre‐eclampsia and eclampsia. BJOG: An International Journal of Obstetrics & Gynaecology, 2016. 123(3): p. 356-366. [DOI:10.1111/1471-0528.13753] [PMID] []
41. Padda J, et al., Efficacy of magnesium sulfate on maternal mortality in eclampsia. Cureus, 2021. 13(8). [DOI:10.7759/cureus.17322]
42. Rimal SP, et al., Loading dose only versus standard dose magnesium sulfate seizure prophylaxis in severe pre-eclamptic women. Journal of the Nepal Medical Association, 2017. 56(208). [DOI:10.31729/jnma.3431]
43. Belfort MA, et al., A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. New England Journal of Medicine, 2003. 348(4): p. 304-311. [DOI:10.1056/NEJMoa021180] [PMID]
44. Coetzee E, Dommisse J, and Anthony J, A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre‐eclampsia. BJOG: An International Journal of Obstetrics & Gynaecology, 1998. 105(3): p. 300-303. [DOI:10.1111/j.1471-0528.1998.tb10090.x] [PMID]
45. Keepanasseril A, et al., Prophylactic magnesium sulphate in prevention of eclampsia in women with severe preeclampsia: randomised controlled trial (PIPES trial). Journal of Obstetrics and Gynaecology, 2018. 38(3): p. 305-309. [DOI:10.1080/01443615.2017.1351931] [PMID]
46. Livingston JC, et al., Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial. Obstetrics & Gynecology, 2003. 101(2): p. 217-220.
https://doi.org/10.1097/00006250-200302000-00004 [DOI:10.1016/S0029-7844(02)03053-3]
47. Seth S, NAGRATH A, and SINGH DK, Comparison of low dose, single loading dose, and standard Pritchard regimen of magnesium sulfate in antepartum eclampsia. Anatolian Journal of Obstetrics & Gynecology, 2010. 2(1).
48. Ekele BA, et al., Magnesium sulphate therapy in eclampsia: the Sokoto (ultra short) regimen. BMC research notes, 2009. 2: p. 1-4. [DOI:10.1186/1756-0500-2-165] [PMID] []
49. Noor S, et al., Magnesium sulphate in the prophylaxis and treatment of eclampsia. Journal of Ayub Medical College Abbottabad, 2004. 16(2).
50. Regmi M, et al., Loading dose versus standard regimen of magnesium sulphate in eclampsia-a randomized trial. Nepal Med Coll J, 2010. 12(4): p. 244-247.
51. Shoaib T, et al., Loading dose of magnesium sulphate versus standard regime for prophylaxis of pre-eclampsia. J Coll Physicians Surg Pak, 2009. 19(1): p. 30-33.
52. Orji E, Ogoke G, and Fasubaa O, O528 efficacy of a single loading dose of magnesium sulphate versus the standard pritchard regimen in the management of severe preeclampsia in an african population. International Journal of Gynecology & Obstetrics, 2012. 119: p. S447-S447. [DOI:10.1016/S0020-7292(12)60958-8]
53. Okusanya B, Garba K, and Ibrahim H, The efficacy of intramuscular loading dose of MgSO4 in severe pre-eclampsia/eclampsia at a tertiary referral centre in Northwest Nigeria. The Nigerian Postgraduate Medical Journal, 2012. 19(2): p. 77-82. [DOI:10.4103/1117-1936.169652] [PMID]
54. Duley L, et al., Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia. Cochrane Database of Systematic Reviews, 2010(8). [DOI:10.1002/14651858.CD000025.pub2]
55. Bhattacharjee N, et al., A randomised comparative study between low-dose intravenous magnesium sulphate and standard intramuscular regimen for treatment of eclampsia. Journal of Obstetrics and Gynaecology, 2011. 31(4): p. 298-303. [DOI:10.3109/01443615.2010.549972] [PMID]
56. Chissell S, et al., Intravenous and intramuscular magnesium sulphate regimens in severe pre-eclampsia. South African Medical Journal, 1994. 84(9): p. 607-610.
57. Adewole I, et al., Magnesium sulphate for treatment of eclampsia: the Nigerian experience. African Journal of Medicine and Medical Sciences, 2000. 29(3-4): p. 239-241.
58. Bhalla AK, Dhall G, and Dhall K, A safer and more effective treatment regimen for eclampsia. Australian and New Zealand journal of obstetrics and gynaecology, 1994. 34(2): p. 144-148. [DOI:10.1111/j.1479-828X.1994.tb02677.x] [PMID]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
